Min Mildred, Afzal Nasima, Maloh Jessica, Dulai Ajay S, Ahmad Nabeel, Pinzauti David, Sivamani Raja K
Integrative Skin Science and Research, Sacramento, CA, USA.
Integrative Research Institute, Sacramento, CA, USA.
Dermatol Ther (Heidelb). 2025 Jun;15(6):1331-1350. doi: 10.1007/s13555-025-01411-4. Epub 2025 Apr 18.
Acne pathogenesis is multifactorial, involving systemic factors including gut dysbiosis, hormones, and chronic inflammation. Probiotics, myoinositol, and plant-derived molecules may modulate acne by targeting these factors. The objective is to compare a synbiotic containing herbs against a myoinositol-based herbal supplement on how they influence acne, the gut microbiome, short chain fatty acids (SCFAs), and hormonal profiles.
This was an 8-week, randomized study involving 36 male and female patients aged 12 to 45 years with non-cystic acne. Subjects received either a synbiotic or a myoinositol-based herbal supplement (MBHS). Acne lesions were counted, stool samples were collected for gut microbiome and SCFA analyses, and hormone collections were performed at baseline, 4, and 8 weeks.
Several gut bacteria increased by at least threefold at both week 4 and 8 in the synbiotic (Erysipelatoclostridium merdavium, Blautia argi, Faecalibacterium prausnitzii, Prevotella copri, Streptococcus sp001556435, Blautia sp900541955) and MBHS group (Megamonas funiformis, Ligilactobacillus ruminis, Prevotella ssp015074785, Prevotella copri, Gca-900199835 sp900176495). Acne lesion counts decreased significantly in both groups at week 4 (p < 0.0001) and week 8 (synbiotic, p < 0.0001; MBHS, p < 0.0001). There were significant and trending increases in stool and plasma SCFAs in both cohorts at week 4 and 8. After 8 weeks of MBHS, 17-OHP and androstenedione significantly decreased from 27.3 to 11.3 pg/ml (p = 0.001) and 94.9 to 68.0 pg/ml (p = 0.04), respectively.
Both the synbiotic and MBHS improved gut health, augmented SCFAs, and reduced lesion counts in those with non-cystic acne. The MBHS may act by reducing hormone levels of 17-OHP and androstenedione.
www.
gov (NCT05919810).
痤疮的发病机制是多因素的，涉及全身因素，包括肠道微生物失调、激素和慢性炎症。益生菌、肌醇和植物源分子可能通过针对这些因素来调节痤疮。目的是比较一种含草药的合生元与一种基于肌醇的草药补充剂对痤疮、肠道微生物群、短链脂肪酸（SCFAs）和激素谱的影响。
这是一项为期8周的随机研究，涉及36名年龄在12至45岁之间的非囊肿性痤疮男女患者。受试者分别接受合生元或基于肌醇的草药补充剂（MBHS）。对痤疮皮损进行计数，收集粪便样本进行肠道微生物群和SCFA分析，并在基线、第4周和第8周采集激素样本。
在合生元组（默氏丹毒梭菌、阿氏布劳特氏菌、普拉梭菌、普氏粪杆菌、链球菌sp001556435、布劳特氏菌sp900541955）和MBHS组（绳状巨单胞菌、瘤胃乳杆菌、普氏菌属ssp015074785、普氏粪杆菌、Gca-900199835 sp900176495）中，几种肠道细菌在第4周和第8周均增加了至少三倍。两组在第4周（p＜0.0001）和第8周（合生元组，p＜0.0001；MBHS组，p＜0.0001）时痤疮皮损计数均显著下降。在第4周和第8周时，两个队列的粪便和血浆SCFAs均有显著且呈上升趋势的增加。服用MBHS 8周后，17-羟孕酮（17-OHP）和雄烯二酮分别从27.3显著降至11.3 pg/ml（p = 0.001）和从94.9降至68.0 pg/ml（p = 0.04）。
合生元和MBHS均改善了肠道健康，增加了SCFAs，并减少了非囊肿性痤疮患者的皮损计数。MBHS可能通过降低17-OHP和雄烯二酮的激素水平发挥作用。
